ICUI

+ Watchlist + Portfolio

ICU Medical, Inc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $157.18
52-Week Range: $112.50 – $192.85
Market Cap: $3.99B
P/E (TTM): 133.93
EPS (TTM): 1.19
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.85
PEG Ratio: 0.08
Return on Equity: 1.41%
Return on Assets: 1.93%
Gross Margin: 38.26%
Operating Margin: 7.53%
Profit Margin: 1.39%
Current Ratio: 2.43
Debt/Equity: 0.60
Total Debt: $1.29B
Free Cash Flow: $163.56M
Revenue Growth: 0.50%
Earnings Growth: -46.90%
Enterprise Value: $4.97B

ICUI Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$2.28B	$2.26B	$2.38B	$2.23B
Cost of Revenue	$1.58B	$1.52B	$1.56B	$1.41B
Gross Profit	$697.76M	$739.87M	$824.78M	$822.04M
Research & Development	$92.98M	$85.34M	$88.61M	$87.50M
Selling, General & Admin	$608.35M	$606.69M	$638.76M	$625.21M
Operating Expenses	$701.33M	$692.04M	$727.38M	$712.71M
Operating Income	-$3.57M	$47.84M	$97.41M	$109.33M
EBITDA	$191.55M	$253.20M	$260.04M	$298.44M
Pretax Income	-$114.41M	-$78.30M	-$66.01M	$4.36M
Income Tax	-$40.12M	-$48.64M	$51.68M	$2.44M
Net Income	-$74.29M	-$29.66M	-$117.69M	$732.00K
Diluted EPS	-3.11	-1.23	-4.83	0.03
Diluted Shares	23.87M	24.09M	24.39M	24.90M

ICUI Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$208.78M	$254.22M	$308.57M	$307.96M
Receivables	$246.90M	$182.15M	$200.14M	$203.91M
Inventory	$696.01M	$709.36M	$584.68M	$615.86M
Current Assets	$1.24B	$1.22B	$1.44B	$1.19B
Total Assets	$4.52B	$4.38B	$4.20B	$4.05B
Current Liabilities	$494.56M	$481.84M	$556.18M	$498.86M
Long-Term Debt	$1.62B	$1.58B	$1.53B	$1.27B
Total Debt	$1.73B	$1.70B	$1.63B	$1.33B
Total Liabilities	$2.43B	$2.26B	$2.24B	$1.93B
Retained Earnings	$837.50M	$807.85M	$690.16M	$690.89M
Shareholders' Equity	$2.09B	$2.12B	$1.97B	$2.12B
Working Capital	$740.64M	$739.43M	$885.80M	$691.69M
Net Debt	$1.44B	$1.37B	$1.27B	$976.70M

ICUI Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$62.13M	$166.20M	$204.03M	$179.85M
Capital Expenditure	-$99.33M	-$93.67M	-$90.21M	-$97.02M
Free Cash Flow	-$161.46M	$72.53M	$113.83M	$82.83M
Depreciation & Amortisation	$235.15M	$228.77M	$219.51M	$200.74M
Stock-Based Compensation	$36.02M	$40.56M	$46.88M	$55.76M
Investing Cash Flow	-$1.91B	-$87.95M	-$88.96M	$122.23M
Financing Cash Flow	$1.64B	-$35.98M	-$55.80M	-$311.52M
Net Change in Cash	-$334.56M	$42.27M	$59.27M	-$9.45M

ICUI Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$604.70M	$548.87M	$536.99M	$540.70M	$530.23M	$551.68M
Cost of Revenue	$394.59M	$340.80M	$336.11M	$337.72M	$324.00M	$316.63M
Gross Profit	$210.11M	$208.06M	$200.88M	$202.99M	$206.23M	$235.05M
Research & Development	$23.29M	$21.87M	$21.25M	$21.09M	$21.28M	$22.70M
Selling, General & Admin	$157.23M	$159.39M	$152.77M	$155.81M	$154.57M	$151.92M
Operating Expenses	$180.52M	$181.26M	$174.02M	$176.90M	$175.85M	$174.62M
Operating Income	$29.59M	$26.80M	$26.86M	$26.09M	$30.38M	$60.43M
EBITDA	$63.80M	$106.41M	$70.52M	$57.71M	$64.56M	$91.34M
Pretax Income	-$10.91M	$33.68M	-$2.51M	-$15.90M	-$3.98M	$23.14M
Income Tax	$4.57M	$1.18M	-$658.00K	-$2.65M	-$34.71M	$7.07M
Net Income	-$15.48M	$35.34M	-$3.40M	-$15.73M	$30.13M	$19.09M
Diluted EPS	-0.63	1.43	-0.14	-0.64	1.20	0.76
Diluted Shares	24.54M	24.71M	24.69M	24.69M	25.18M	25.04M

ICUI Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$289.70M	$300.02M	$299.73M	$307.96M	$288.33M	$298.30M
Receivables	$204.68M	$219.17M	$217.23M	$203.91M	$226.82M	$218.63M
Inventory	$590.33M	$616.47M	$622.44M	$615.86M	$605.59M	$607.42M
Current Assets	$1.42B	$1.18B	$1.21B	$1.19B	$1.21B	$1.21B
Total Assets	$4.18B	$4.11B	$4.10B	$4.05B	$4.01B	$3.97B
Current Liabilities	$549.02M	$482.78M	$492.90M	$498.86M	$517.90M	$498.36M
Long-Term Debt	$1.49B	$1.34B	$1.31B	$1.27B	$1.26B	$1.21B
Total Debt	$1.60B	$1.39B	$1.36B	$1.33B	$1.33B	$1.27B
Total Liabilities	$2.20B	$1.99B	$1.98B	$1.93B	$1.90B	$1.82B
Retained Earnings	$674.68M	$710.02M	$706.62M	$690.89M	$721.02M	$740.11M
Shareholders' Equity	$1.99B	$2.12B	$2.13B	$2.12B	$2.11B	$2.15B
Working Capital	$874.89M	$697.34M	$714.39M	$691.69M	$695.34M	$712.54M
Net Debt	$1.25B	$1.04B	$1.01B	$976.70M	$992.25M	$932.90M

ICUI Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$51.33M	$11.21M	$56.71M	$60.60M	$38.91M	$80.15M
Capital Expenditure	-$16.85M	-$22.00M	-$31.75M	-$26.41M	-$13.21M	-$20.16M
Free Cash Flow	$34.47M	-$10.79M	$24.96M	$34.19M	$25.70M	$59.99M
Depreciation & Amortisation	$49.45M	$49.66M	$50.80M	$50.83M	$50.00M	$49.64M
Stock-Based Compensation	$12.18M	$14.46M	$15.24M	$13.88M	$14.01M	$11.87M
Investing Cash Flow	-$16.81M	$187.46M	-$30.03M	-$18.39M	-$11.21M	-$20.14M
Financing Cash Flow	-$56.34M	-$195.01M	-$25.69M	-$34.48M	-$44.12M	-$50.23M
Net Change in Cash	-$21.82M	$3.65M	$993.00K	$7.72M	-$16.42M	$9.78M

Market Snapshot

About

ICU Medical is a medical device company developing, manufacturing, and selling innovative medical products used in infusion therapy, oncology, and critical care applications. The company's product portfolio includes IV therapy systems, infusion pumps, dedicated and non-dedicated IV sets, needleless connector products, and closed system transfer devices for hazardous drug handling. ICU Medical serves hospitals, clinics, ambulatory care centers, and other healthcare facilities worldwide. The company has grown through internal innovation and strategic acquisitions, including the acquisition of Smiths Medical's infusion systems and vascular access product lines, making it a comprehensive provider of infusion therapy solutions.